Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
- 04.11.2022
- Original Article
Erschienen in:
- Verfasst von
- Takashi Ueda
- Kazutoshi Fujita
- Mitsuhisa Nishimoto
- Takumi Shiraishi
- Masatsugu Miyashita
- Naruhiro Kayukawa
- Yuichi Nakamura
- Satoshi Sako
- Ryota Ogura
- Atsuko Fujihara
- Takafumi Minami
- Fumiya Hongo
- Koji Okihara
- Kazuhiro Yoshimura
- Hirotsugu Uemura
- Osamu Ukimura
- Erschienen in
- World Journal of Urology | Ausgabe 12/2022
Abstract
Purpose
There is a discrepancy in the efficacy of abiraterone acetate for overall survival (OS) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). This study aimed to identify predictive factors for the efficacy of abiraterone acetate for OS in high-risk mHSPC patients by analyzing them over a longer observation period.
Methods
Five hundred high-risk mHSPC patients were retrospectively identified at our hospital and affiliated hospitals in the Kindai Oncology Study Group and Kyoto Prefectural University of Medicine Oncology Study Group between December 2013 and March 2022. Two hundred patients were treated with abiraterone acetate (1000 mg/day) plus prednisolone (5 mg/day) combined with androgen deprivation therapy (ADT). A total of 300 patients were treated with bicalutamide (80 mg/day) in combination with ADT.
Results
OS was not significantly different between the two treatments in the overall cohort (p = 0.1643). In the subgroup without Gleason pattern 5 at the primary lesion, OS was significantly better in patients treated with abiraterone acetate than in those treated with bicalutamide (p = 0.0192). In the subgroup with Gleason pattern 5 at the primary lesion, no significant difference was found between the two treatments (p = 0.1799). Univariate and multivariate analyses in the subgroup without Gleason pattern 5 at the primary lesion suggested that abiraterone therapy may be an important and independent predictor of OS in high-risk mHSPC patients.
Conclusion
The presence of Gleason pattern 5 at the primary lesion may be a predictor for high-risk mHSPC patients who could benefit from abiraterone acetate treatment.
Anzeige
- Titel
- Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
- Verfasst von
-
Takashi Ueda
Kazutoshi Fujita
Mitsuhisa Nishimoto
Takumi Shiraishi
Masatsugu Miyashita
Naruhiro Kayukawa
Yuichi Nakamura
Satoshi Sako
Ryota Ogura
Atsuko Fujihara
Takafumi Minami
Fumiya Hongo
Koji Okihara
Kazuhiro Yoshimura
Hirotsugu Uemura
Osamu Ukimura
- Publikationsdatum
- 04.11.2022
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
World Journal of Urology / Ausgabe 12/2022
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726 - DOI
- https://doi.org/10.1007/s00345-022-04200-2
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
